CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to advance oligonucleotide-based therapies by developing innovative delivery systems for RNA and DNA therapeutics. It focuses on creating amphoteric liposomes that improve the safety and efficacy of drug delivery to treat inflammatory diseases.
The past year has been exciting for oligonucleotide-based drug discovery and development.
The Nobel Prize was awarded to Mello and Fire for discovering RNA interference.
There was also big investment from the Pharmaceutical industry to Biotechnology companies-pioneers in oligonucleotide therapeutics such as Sirna, Alnylam and Isis, all US-based.
High expectations were therefore raised but further progress is hampered by the issue of systemic delivery; siRNA oligonucleotides are ineffective in vi…
BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, HALLE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Greece, Rethimno
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, DRESDEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
